Table 3. Summary of meta-analysis results in the achievemnt of the outcomes including only clinical trials.

Outcome	No. of studies [ref]	No. of patients experimental/control group	No. (%) of events experimental/control group	RR (efficacy)	95% Confidence interval (efficacy)	P-value	Heterogeneity test (I2, %; P)
Treatment failure	3 [10,11,13]	686/689	77/93	0.86	0.48–1.54	0.608	65.7%, 0.054
Virological failure	3 [10,11,13]	686/680	10/13	0.82	0.36–1.86	0.635	0.0%, 0.498
Adverse drugs leading to discontinuation	3 [10,11,13]	686/680	29/8	3.38	1.58–7.24	0.002	0.0%, 0.758
Appearance of mutation	3 [10,11,13]	686/680	3/0	2.48	0.33–18.68	0.379	0.0%, 0.631

RR, risk ratio.